Lymphangioleiomyomatosis
Name
Institution
Course
Instructor
Date
Lymphangioleiomyomatosis
Lymphangioleiomyomatosis (LAM) is a rare disease that is exclusive to women and mainly affects those between the ages of 20 years to 40 years. It is characterized by progressive and indolent growth of the smooth muscles in the pulmonary blood vessels, lungs, pleurae, and lymphatics. Whites are often at a higher risk, and the condition affects one in every one million people. Usually, the disease’s diagnosis is based on the presenting symptoms, where a high-resolution CT scan is often used. The disease is a genetic disorder often inherited with tuberous sclerosis complex, or it can sometimes be sporadic. The development of the condition is often linked to impaired functioning of the lungs. The average age for diagnosis of the condition is approximately 35 years (McCormack et al., 2016). It is essential to conduct studies on the condition to develop a strategy to prevent the condition. The paper gives detailed information on the condition, its diagnostic, and treatment approaches.
Cause and Development
Since LAM is a rare disease, not too much studies have been conducted on it, and therefore, its leading cause is still not very clear to most scholars. The idea that female sex hormones have some level of significance in the pathogenesis of the condition remains unapproved. Even though the disease often arises spontaneously, it bears several similarities to the pulmonary findings of the disease. The condition has often been witnessed among patients with tuberous sclerosis, and some scholars have considered the condition as a form of fruste for tuberous sclerosis. Cases of mutation within the tuberous sclerosis complex-2 gene have been witnessed within the angiomyolipoma and the LAM cells (Xu et al., 2020). Angiomyolipomas are benign renal hamartomas made up of smooth muscles, adipose tissues, and blood vessels. It often occurs in up to more than 50 percent of the patients with LAM.
So far, the observations that have been made regarding the development of the disease gives a suggestion of either one of the two possibilities for the cause of the condition. LAM represents a sinister, low-grade, and metastasizing neoplasm that may be emerging from the uterus and then spreads within the lymphatic system of the body. Also, some of the mosaicism for the mutations of the TSC-2 in the kidneys and the lungs leads to a focus of the disease, often superimposed against a background of a normal cell within the tissues. However, the multiple discrete signs of the disease can sometimes be expected (Bee et al., 2018).
Signs and Symptoms
The condition is associated with a wide range of symptoms that tend to form the basis for the diagnostic procedures. The initial symptoms of LAM include dyspnea, and in some cases, chest pain, cough, and hemoptysis. There are always very few signs of the condition. However, some women tend to exhibit signs of rhonchi and crackles. Most of the patients tend to presents the signs of pneumothorax (McCormack et al., 2016). Under severe cases, the patients also develop the manifestations of lymphatic obstructions as chylothorax, chyluria, and chylous ascites. Studies have indicated that the symptoms tend to worsen during the periods of pregnancy. The cases of renal Angiolipomas, even though always asymptomatic, tend to cause bleeding in a case where they enlarge and are characterized by flank pain or hematuria manifestations. The median survival period is likely to be more than eight years from the time of diagnosis (Xu et al., 2020). The functioning of the lungs tends to decline by about 2 to 3 times faster as compared to the case of healthy people. Women need to understand that progression is likely to accelerate during times of pregnancy.
Diagnosis
LAM diagnosis is often made among young women with interstitial changes and dyspnea. Diagnosis is most recommended when an increased volume of lungs as revealed by an x-ray of the chest cavity, chylous effusion, and spontaneous pneumothorax. On specific occasions, the condition has been misdiagnosed as interstitial lung disease. HRCT is often done for every patient who is suspected of having the condition. The presence of LAM is always indicated by the findings of multiple, diffusely distributed, and small cysts. Serum VEGF-D testing is also a recommended diagnostic approach. Most of the women with LAM tend to have an elevated level of serum VEGF-D and remain standard for women with the other forms of cystic lung diseases (Gupta et al., 2017). Even though an elevated level can be confirmatory for LAM, an average level doesn’t exclude the processes of diagnosis.
In a case where the above tests are non-diagnostic, a biopsy can be used. A finding that indicates an abnormal proliferation of the smooth muscle cells often associated with the histologic examination’s cystic changes is confirmatory for the disease. The pulmonary functions tests are often a test for the diagnostic process and are particularly useful for monitoring purposes. Typical findings are always restrictive and the mixed obstructive or obstructive pattern. The lungs are always hyperinflated due to the increase in the lungs’ capacity and the volume of the thoracic gases (Xu et al., 2020). Gas trapping is always present. LAM often reduces the carbon monoxide diffusion capacity, and most patients tend to experience decreased performance in exercise.
Treatment
The standard treatment approach for LAM is a lung transplant, even though the disorder can recur in the transplanted lungs. Recent data has suggested that sirolimus can be important in stabilizing or slow down the functions of the pulmonary among patients who have a moderate impairment of the lungs. There are a number of alternative treatment approaches, such as hormonal manipulation, that are considered to be very ineffective and therefore not recommended. Pneumothorax is often very challenging to manage as it always recurs, less responsive to the standard measures, and is less bilateral. For a case of a recured pneumothorax, it is important to make use of the talc, abrasion, and the chemical pleurodesis (Gupta et al., 2017). Embolization is essential as it helps in preventing bleeding in the case of an angiomyolipoma.
In conclusion, LAM is characterized by progressive and indolent growth of the smooth muscles in the pulmonary blood vessels, lungs, pleurae, and the lymphatics. The condition has often been witnessed among patients with tuberous sclerosis, and some scholars have considered the condition as a form of fruste for tuberous sclerosis. The prognosis of the condition is often unclear since it is often a rare case. This is also attributed to the fact that the clinical cause of the patients with LAM is always variable. Generally, the disease is slowly progressive and results in cases of respiratory failure and death. However, the time for death is widely varied as per the reports.
References
Bee, J., Fuller, S., Miller, S., & Johnson, S. R. (2018). Lung function response and side effects to rapamycin for lymphangioleiomyomatosis: a prospective national cohort study. Thorax, 73(4), 369-375.
Gupta, N., Finlay, G. A., Kotloff, R. M., Strange, C., Wilson, K. C., Young, L. R., … & Ryu, J. H. (2017). Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, Transbronchial lung biopsy, and pleural disease management. An official American Thoracic Society/Japanese respiratory society clinical practice guideline. American journal of respiratory and critical care medicine, 196(10), 1337-1348.
McCormack, F. X., Gupta, N., Finlay, G. R., Young, L. R., Taveira-DaSilva, A. M., Glasgow, C. G., … & Strange, C. (2016). Official American Thoracic Society/Japanese Respiratory Society clinical practice guidelines: lymphangioleiomyomatosis diagnosis and management. American journal of respiratory and critical care medicine.
Xu, K. F., Xu, W., Liu, S., Yu, J., Tian, X., Yang, Y., … & Zhang, T. (2020, April). Lymphangioleiomyomatosis. In Seminars in respiratory and critical care medicine (Vol. 41, No. 02, pp. 256-268). Thieme Medical Publishers.